SHR-1209

DRUG6 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

Conditions

Familial HypercholesterolemiaHypercholesteremiaHypercholesterolemia and HyperlipidemiaHyperlipidemiaMixed HyperlipemiaPrimary Hypercholesterolemia

Phase 1

The PK/PD Study of A Single Subcutaneous Injection of SHR-1209 in Healthy Subjects

CompletedNCT03634436

Jiangsu HengRui Medicine Co., Ltd.Hypercholesteremia

Start: 2018-08-30End: 2019-05-28Updated: 2022-08-03

The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia

CompletedNCT03944109

Jiangsu HengRui Medicine Co., Ltd.Hyperlipidemia

Start: 2019-06-20End: 2020-12-22Updated: 2022-11-30

Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy Volunteers

CompletedNCT05370950

Jiangsu HengRui Medicine Co., Ltd.Hypercholesterolemia and Hyperlipidemia

Start: 2022-05-25End: 2022-12-31Updated: 2023-01-12

Phase 2

A Study to Determine the Safety, Tolerability, and Efficacy of SHR-1209 in Patients With Familial Hypercholesterolemia

Jiangsu HengRui Medicine Co., Ltd.Familial Hypercholesterolemia

Start: 2020-09-01End: 2021-08-31Target: 8Updated: 2020-07-02

Phase 3

SHR - 1209 Treatment Efficacy and Safety of the Patients With Hypercholesterolemia Ⅲ Period Clinical Research

CompletedNCT04844125

Jiangsu HengRui Medicine Co., Ltd.Primary Hypercholesterolemia

Start: 2021-04-14End: 2022-08-12Updated: 2023-04-25

Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage

CompletedNCT04849000

Jiangsu HengRui Medicine Co., Ltd.Mixed Hyperlipemia, Primary Hypercholesterolemia

Start: 2021-04-23End: 2023-01-13Updated: 2023-05-19

Related Papers

Abstract 4368112: Immunogenicity of Recaticimab Does Not Impact Its Efficacy in Patients with Dyslipidemia: A Pooled Analysis of Three Phase III and One Phase Ib/II Studies

Circulation2025-11-03

Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study.

2025-10-01

Population Pharmacokinetics and Pharmacodynamics Modeling for the Use of Recaticimab in Healthy Volunteers and Patients with Hypercholesterolemia.

2025-06-301 citations

A Phase I Study to Evaluate the Relative Bioavailability, Pharmacodynamics, and Safety of a Single Subcutaneous Injection of Recaticimab at Three Different Sites in Healthy Chinese Subjects.

2025-04-191 citations

PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study.

2022-01-1818 citations